Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001066054 | SCV001231047 | benign | Episodic ataxia type 2; Developmental and epileptic encephalopathy, 42 | 2023-04-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002554480 | SCV003744895 | uncertain significance | Inborn genetic diseases | 2022-02-10 | criteria provided, single submitter | clinical testing | The c.6143C>T (p.P2048L) alteration is located in exon 42 (coding exon 42) of the CACNA1A gene. This alteration results from a C to T substitution at nucleotide position 6143, causing the proline (P) at amino acid position 2048 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV003222214 | SCV003918074 | uncertain significance | not provided | 2023-03-01 | criteria provided, single submitter | clinical testing | CACNA1A: PP2 |